Display Settings: Abstract
Cancer. 1992 Nov 15;70(10):2475-83.
Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y, et al.
Department of Surgery, Hiroshima University, Japan.
BACKGROUND: A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition
of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with
estrogen receptor (ER)-positive tumors and the addition of PSK, a biologic response modifier, to MMC+FT chemotherapy
for patients with ER-negative tumors in operable Stage IIA, IIB, and IIIA cancer. The doses used were 20 mg of oral TAM
daily, 600 mg of oral FT daily, and 3 g of oral PSK daily for 2 years. Intravenous MMC (13 mg/m2) was given on the day
of operation. METHODS: A total of 967 patients were entered and randomized by stratification based on ER status and
staging (1978 International Union Against Cancer [UICC] criteria at the time of trial execution). Of 967 patients, 914
(94.5%) were evaluable. At 5-year follow-up, significant prolonged overall survival (OS) and relapse-free survival (RFS)
times were seen with the addition of TAM in patients with ER-positive and Stage IIIA T3N0 cancer (1987 UICC-American
Joint Committee on Cancer [AJCC] criteria); however, no significant survival benefit from TAM was seen in patients with
ER-positive and Stage IIA T2N1 cancer. There was no significant difference between regimens, with or without PSK, in
patients with ER-negative disease. RESULTS: Results of subset analyses suggested a benefit from TAM in
postmenopausal patients with ER-positive and Stage IIA T2N1 cancer and a benefit from PSK in patients with
node-negative, ER-negative, and Stage IIA T2N1 cancer. CONCLUSIONS: The 5-year results of the current trial showed a
survival advantage by the addition of TAM to chemotherapy in patients with ER-positive and Stage IIIA T3N0 cancer.
PMID: 1423177 [PubMed – indexed for MEDLINE]
U.S. National Library of Medicine
National Institutes of Health
Publication Types, MeSH Terms, Substances